Patients

Precision Medicine Assist In Cancer Monitoring

ACTMonitor®+ Grasps The Changes Of Cancer Genomic Mutations After Treatment

In the medical journey of cancer treatment, precision medicine is recognized as a modern and favored way for healthcare system to take care of cancer patients more easily. Challenges of identifying the right drug to every cancer patient while new drugs are emerging for specific genomic mutations can be tackled strategically by having cancer patients’ unique cancer genomic profiles. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well as USFDA committed from 2018. The wave of precision medicine also increases approvals of companion diagnostics, bringing ACT Genomics’ genomic profiling service on the waiting list of USFDA approval.

Why You Need To Know About Precision Medicine

Top global pharma companies fasten the pace to conduct clinical trials of precision medicine, which requires cancer patients’ genomic information via genomic profiling.This evolution affects most hospitals, so you need to get prepared for the genomic profiling if you are always looking for a new treatment.

   

Clinical Trials Highlights

 http://www.actgenomics.com/en/clinical_news/list

What A Blood Test Can Do For Me?

 Even the best plan on earth still needs constant monitoring and adjustment to keep up with the changes. Cancer cell’s complexity makes it like a multifaceted beast, when one side being controlled, another side rages. While cells release DNA into blood from time to time, if the DNA released from tumor, circulating tumor DNA (ctDNA), can be captured and analyzed by cancer genomic profiling, more real-time clues of cancer cell can be revealed. Through simple blood test, drug resistance is no longer an annoying issue, and it can also detect the signal of relapse and serve as a non-invasive alternative option to surgical biopsies.

Image title


Common Problems In Cancer Treatment:

∙ Chemotherapy and surgery are the only options according to NCCN guideline or single gene test result

∙ Complicated and metastases, hard to know the appropriate drugs

∙ Ineffective treatment, and cancer relapse after targeted therapy

∙ Pursue for immunotherapy, targeted therapy and wondering the effect


Diagnostic Solutions For Various Cancers

Through Next Generation Sequencing (NGS), ACTMonitor®+ cancer monitoring testing decodes 8-50 genes to map drug options via many clinical researches, not limit to single clinical treatment guideline and controls the growth mechanism from genomic level to enable more treatment strategy with higher success rate.

Suitable for breast, lung, colon cancer and other solid tumors. If single gene test does not bring satisfying result, NGS genomic profiling can detect special genomic mutations for better treatment ; if recurrence or metastases is found, treatment can be modified according to NGS genomic profiling result to overcome drug resistance.


Fusion Gene Test Can Bring Treatment Advantages As Follows:

More humanized process : Avoid multiple biopsies and time cost of single gene test, few specimen required for various fusion gene detection at once.

✔ More ideal treatment  : Find proper targeted options

Plan medical budget more intelligently  : Evaluate options before treatment according to genomic information, to ensure success rate and avoid waste of medical budget. 


Listen To The Successful Fighters' Stories

Many cancer patients are diagnosed late stage, and some patients will know precision medicine is because they have medical background or being recommended by physicians. Listen to their stories and help them bring hope to more people.


Cancer Patient Stories :
http://www.actgenomics.com/en/patient#arc_story 


癌症照護

ACTMonitor®+ Cancer Monitoring Testing

∙ Who Can Use : 

∙Who are unable to undergo surgery

∙Who have developed drug resistance

∙With risk of cancer recurrence

∙Who wish to monitor treatment response

∙ Specimen Type : Blood sample

∙ Turnaround Time :10 working days after qualified sample is received